Chemotinib (Imatinib) Tablet

Generic brands for Imatinib Injection  Available in India Brand Name Chemotinib Generic Name Imatinib Strength 400mg Manufacturer Neon Laboratories Ltd

Description

Description

This page contains brief details about the drug imatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Imatinib is a targeted anticancer treatment drug that was approved for its medical use on 10th May 2001.

Mechanism of Action of Imatinib

Imatinib is a biological agent that acts as targeted drug therapy in cancer treatment. It is an anticancer medication that belongs to the category of tyrosine kinase inhibitors. It acts against a protein called BCR-ABL tyrosine kinase and interferes with cell signalling, ultimately stopping the growth and spread of cancer cells.

Uses of Imatinib

Imatinib has been developed to treat a type of stomach cancer (Gastrointestinal stromal tumour), chronic eosinophilic leukemia, Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase and chronic phase, Philadelphia chromosome acute lymphoblastic leukemia, myelodysplastic syndrome and skin cancer (Dermatofibrosarcoma protuberans).

Imatinib Dosage available

Imatinib is available in the form of tablets and capsules in the doses 100mg and 400mg. Your healthcare provider will calculate the ideal dose according to your condition. Take Imatinib Tablet/capsule with a large glass of water. If you have trouble swallowing, dissolve the tablet or capsule contents in water or apple juice and consume them.

We can ship to :

How to Get Access

FAQ’s

News/Updates

References

  1. KD Tripathi, Anticancer Drugs, Essentials of Medical Pharmacology, 8th Edition, 2019, 915-936.
  2. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Goodman & Gilman’s Pharmacological Basis of Therapeutics, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, 13th Edition, 2018, 1203-1236.
  3. Novartis Pharmaceuticals Corporation, US Food & Drug Administration, [Revised on Aug 2022] [Accessed on 10th Sep 2022], https://www.novartis.com/us-en/sites/novartis_us/files/gleevec_tabs.pdf